TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T20251	Voltage-gated potassium channel Kv11.1	D03DIG	Codeine	Approved	5284371	C18H21NO3	299.4	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O	IC50 = 301995.17 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D03FLC	Lamotrigine	Approved	3878	C9H7Cl2N5	256.089	C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N	IC50 = 229086.77 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D08CDI	Lapatinib	Approved	208908	C29H26ClFN4O4S	581.1	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	IC50 = 630957.34 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D0AO5H	Trimethoprim	Approved	5578	C14H18N4O3	290.32	COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N	IC50 = 239883.29 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D0D7KC	Alvimopan	Approved	5488548	C25H32N2O4	424.5	C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O	IC50 = 794328.23 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D0K3QS	Everolimus	Approved	6442177	C53H83NO14	958.2	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC	IC50 = 501187.23 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D0L3MP	VRX496	Approved	64143	C32H45N3O4S	567.8	CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O	IC50 = 501187.23 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D0O3FG	Desvenlafaxine	Approved	125017	C16H25NO2	263.37	CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O	IC50 = 251188.64 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D0R1RS	Indomethacin	Approved	3715	C19H16ClNO4	357.8	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O	IC50 = 301995.17 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D0T8GD	Nicotine	Approved	89594	C10H14N2	162.23	CN1CCC[C@H]1C2=CN=CC=C2	IC50 = 244299.74 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D0T8XB	Anagliptin	Approved	44513473	C19H25N7O2	383.4	CC1=NN2C=C(C=NC2=C1)C(=O)NCC(C)(C)NCC(=O)N3CCC[C@H]3C#N	IC50 > 500000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D0X4RN	Lidocaine	Approved	3676	C14H22N2O	234.34	CCN(CC)CC(=O)NC1=C(C=CC=C1C)C	IC50 = 263026.8 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D0X5ZI	Ambrisentan	Approved	6918493	C22H22N2O4	378.4	CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C	IC50 = 501187.23 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B0YX8V	6-Cyano-N-[(1R)-1-[1-ethyl-6-(trifluoromethyl)imidazo[4,5-c]pyridin-2-yl]ethyl]pyridine-3-sulfonamide	Investigative	24985395	C17H15F3N6O2S	424.4	CCN1C2=CC(=NC=C2N=C1[C@@H](C)NS(=O)(=O)C3=CN=C(C=C3)C#N)C(F)(F)F	IC50 > 200000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B15XCF	(9S)-9-Amino-9-deoxoerythromycin	Investigative	83952	C37H70N2O12	735	CC[C@@H]1[C@@]([C@@H]([C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)N)C)O)(C)O	IC50 = 316227.77 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B19DRT	(3R,4R)-4-Amino-3-(pyrrolidine-1-carbonyl)-1-(quinoxaline-3-carbonyl)pyrrolidin-2-one	Investigative	44443420	C18H19N5O3	353.4	C1CCN(C1)C(=O)[C@H]2[C@H](CN(C2=O)C(=O)C3=NC4=CC=CC=C4N=C3)N	IC50 > 300000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B1QS9R	6-[[[4-[(1R)-1-Amino-2-(7-fluoro-4-methyl-2-oxoquinolin-1-yl)ethyl]cyclohexyl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one	Investigative	46206324	C26H30FN5O3	479.5	CC1=CC(=O)N(C2=C1C=CC(=C2)F)C[C@@H](C3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5)N	IC50 > 333000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B2XRM5	6-Cyano-N-[(1R)-1-(6-cyclopropyl-1-ethylimidazo[4,5-c]pyridin-2-yl)ethyl]pyridine-3-sulfonamide	Investigative	24985745	C19H20N6O2S	396.5	CCN1C2=CC(=NC=C2N=C1[C@@H](C)NS(=O)(=O)C3=CN=C(C=C3)C#N)C4CC4	IC50 > 200000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B30XNR	5-(2-(1,4''-Bipiperidin-1''-yl)thiazolo[4,5-b]pyridin-6-yl)pyridin-2-ol	Investigative	45482688	C21H25N5OS	395.5	C1CCN(CC1)C2CCN(CC2)C3=NC4=C(S3)C=C(C=N4)C5=CNC(=O)C=C5	IC50 = 323333.33 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B3W1CG	1-Cyclopropyl-6-fluoro-7-[(8Z)-8-methoxyimino-2,6-diazaspiro[3.4]octan-6-yl]-4-oxo-2,3-dihydro-1,8-naphthyridine-3-carboxylic acid	Investigative	53326693	C19H22FN5O4	403.4	CO/N=C/1\\CN(CC12CNC2)C3=C(C=C4C(=O)C(CN(C4=N3)C5CC5)C(=O)O)F	IC50 = 218776.16 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B62CEQ	(3R,4R)-4-[(3S)-3-(3-Fluoro-6-methoxyquinolin-4-yl)-3-hydroxypropyl]-1-[3-(1,2-oxazol-5-yl)cyclobutyl]piperidine-3-carboxylic acid	Investigative	137660546	C26H30FN3O5	483.5	COC1=CC2=C(C(=CN=C2C=C1)F)[C@H](CC[C@@H]3CCN(C[C@@H]3C(=O)O)C4CC(C4)C5=CC=NO5)O	IC50 > 300000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B6AWL2	2-[[[4-[(1R)-1-Amino-2-(6-fluoro-7-methoxy-2-oxoquinoxalin-1-yl)ethyl]cyclohexyl]amino]methyl]-8H-pyrimido[5,4-b][1,4]oxazin-7-one	Investigative	118720931	C24H28FN7O4	497.5	COC1=C(C=C2C(=C1)N(C(=O)C=N2)C[C@@H](C3CCC(CC3)NCC4=NC=C5C(=N4)NC(=O)CO5)N)F	IC50 > 333000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B79QBZ	(3R)-3-[[4-(2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)-2-oxabicyclo[2.2.2]octan-1-yl]methyl]-5-fluoro-3-hydroxy-1,7-diazatricyclo[6.3.1.04,12]dodeca-4(12),5,7,9-tetraen-11-one	Investigative	118736667	C26H27FN4O5	494.5	C1CC2(CCC1(CO2)NCC3=CC4=C(C=N3)OCCO4)C[C@@]5(CN6C(=O)C=CC7=NC=C(C5=C76)F)O	IC50 = 764000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B7RY1G	CID 25008765	Investigative	25008765	C25H26N6O4	474.5	C1CN(C[C@H]([C@H]1NCC2=NC3=C(C=C2)OCC(=O)N3)O)CCN4C(=O)C=CC5=C4C=C(C=C5)C#N	IC50 = 305000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	B97HXD	4-[6-(Azetidine-1-carbonyl)-5-fluoropyridin-3-yl]oxy-2-ethyl-N-(5-methylpyrazin-2-yl)indazole-6-carboxamide	Investigative	46911124	C24H22FN7O3	475.5	CCN1C=C2C(=CC(=CC2=N1)C(=O)NC3=NC=C(N=C3)C)OC4=CC(=C(N=C4)C(=O)N5CCC5)F	IC50 > 300000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BB02YS	3-[[4-(3,4-Dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carbonyloxymethyl)piperidin-1-yl]methyl]cyclopentane-1-carboxylic acid	Investigative	118712578	C25H32N2O5	440.5	C1CN2C3=CC=CC=C3C(=C2OC1)C(=O)OCC4CCN(CC4)CC5CCC(C5)C(=O)O	IC50 = 209000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BD2U7Z	N-(4-Chlorophenyl)-2-[5-methoxy-3-[(E)-[(4-methylphenyl)sulfonylhydrazinylidene]methyl]indol-1-yl]acetamide	Investigative	73349556	C25H23ClN4O4S	511	CC1=CC=C(C=C1)S(=O)(=O)N/N=C/C2=CN(C3=C2C=C(C=C3)OC)CC(=O)NC4=CC=C(C=C4)Cl	IC50 = 418350 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BF12KZ	N-Ethyl-2-[3-(trifluoromethyl)phenyl]ethanamine	Investigative	53326682	C11H14F3N	217.23	CCNCCC1=CC(=CC=C1)C(F)(F)F	IC50 = 537031.8 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BF1G9R	CID 60200128	Investigative	60200128	C25H26N6O4	474.5	C1CN(C[C@@H]([C@@H]1NCC2=NC3=C(C=C2)OCC(=O)N3)O)CCN4C(=O)C=CC5=C4C=C(C=C5)C#N	IC50 > 333000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BF29IR	2-[[[4-[(1R)-1-Amino-2-(7-methoxy-2-oxoquinoxalin-1-yl)ethyl]cyclohexyl]amino]methyl]-8H-pyrimido[5,4-b][1,4]oxazin-7-one	Investigative	46205345	C24H29N7O4	479.5	COC1=CC2=C(C=C1)N=CC(=O)N2C[C@@H](C3CCC(CC3)NCC4=NC=C5C(=N4)NC(=O)CO5)N	IC50 > 333000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BG8AX4	(2R)-2-[4-[[[(2S)-3-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-1,3-thiazolidine-2-carbonyl]amino]methyl]anilino]-3-methylbutanoic acid;hydrochloride	Investigative	24860299	C26H32ClF3N4O4S	589.1	CC(C)[C@H](C(=O)O)NC1=CC=C(C=C1)CNC(=O)[C@H]2N(CCS2)C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N.Cl	EC50 = 408000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BGQ2U5	2-[[2-[(3R)-3-Aminopiperidin-1-yl]-7-bromo-4-oxo-5H-pyrrolo[3,2-d]pyrimidin-3-yl]methyl]benzonitrile	Investigative	57385073	C19H19BrN6O	427.3	C1C[C@H](CN(C1)C2=NC3=C(C(=O)N2CC4=CC=CC=C4C#N)NC=C3Br)N	IC50 > 300000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BHRL26	(3S)-3-[[4-(2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)piperidin-1-yl]methyl]-5,10-difluoro-3-hydroxy-1,7-diazatricyclo[6.3.1.04,12]dodeca-4(12),5,7,9-tetraen-11-one	Investigative	23634277	C24H25F2N5O4	485.5	C1CN(CCC1NCC2=CC3=C(C=N2)OCCO3)C[C@@]4(CN5C6=C4C(=CN=C6C=C(C5=O)F)F)O	IC50 = 289000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BJ6NL2	Chembl4283796	Investigative	138964067	C19H23FN4O4S2	454.5	CCN(CC(=O)N1CCC[C@H]1C2=CC(=C(S2)C)C(=O)NC3=NC=C(S3)F)CC(=O)O	IC50 > 300000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BJH1K2	2-((2R,3S,4R,5R,6S,7R,9R,10R,11S,12S,13R)-2-Ethyl-3,4,9-trihydroxy-10-((2S,3R,4S,6R)-3-hydroxy-4-(isopropyl(methyl)amino)-6-methyltetrahydro-2H-pyran-2-yloxy)-12-((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yloxy)-3,5,7,9,11,13-hexamethyl-14-oxooxacyclotetradecan-6-yloxy)-N-methylacetamide	Investigative	45483679	C42H78N2O14	835.1	CC[C@@H]1[C@@]([C@@H]([C@H]([C@H]([C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C(C)C)O)(C)O)C)OCC(=O)NC)C)O)(C)O	IC50 = 411000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BM0H1N	2-(trans-4-(4-(7-Aminopyrazolo[1,5-a]pyrimidin-6-yl)phenyl)cyclohexyl)acetic acid	Investigative	56933229	C20H22N4O2	350.4	C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=C(N4C(=CC=N4)N=C3)N	IC50 > 300000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BMI7R9	2-[[2-[(3R)-3-Aminopiperidin-1-yl]-6-methyl-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl]benzonitrile	Investigative	57385070	C20H22N6O	362.4	CC1=CC2=C(N1)N=C(N(C2=O)CC3=CC=CC=C3C#N)N4CCC[C@H](C4)N	IC50 > 300000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BMV0S2	2-[[2-[(3R)-3-Aminopiperidin-1-yl]-6-bromo-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl]benzonitrile	Investigative	57385071	C19H19BrN6O	427.3	C1C[C@H](CN(C1)C2=NC3=C(C=C(N3)Br)C(=O)N2CC4=CC=CC=C4C#N)N	IC50 > 300000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BMWG84	6H-Pyrimido[5,4-b][1,4]oxazin-7(8H)-one, 2-[[[trans-4-[(1R)-1-amino-2-(7-fluoro-2-oxo-1(2H)-quinoxalinyl)ethyl]cyclohexyl]amino]methyl]-	Investigative	46206000	C23H26FN7O3	467.5	C1CC(CCC1[C@H](CN2C3=C(C=CC(=C3)F)N=CC2=O)N)NCC4=NC=C5C(=N4)NC(=O)CO5	IC50 > 333000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BN8C0R	1-[2-[(3R,4S)-4-(2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)-3-fluoropiperidin-1-yl]ethyl]-2-oxoquinoline-7-carbonitrile	Investigative	25008769	C25H26FN5O3	463.5	C1CN(C[C@H]([C@H]1NCC2=CC3=C(C=N2)OCCO3)F)CCN4C(=O)C=CC5=C4C=C(C=C5)C#N	IC50 > 200000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BO8U6X	Methyl (4aS,6aR,6bS,8aR,12R,12aS,14aR,14bS)-10-[[4-[[(4S)-4-amino-5-methoxy-5-oxopentanoyl]amino]phenyl]methoxy]-11-cyano-12-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-14-oxo-3,4,5,6,7,8,8a,12,14a,14b-decahydro-1H-picene-4a-carboxylate	Investigative	137647489	C45H61N3O8	772	C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4([C@H](C(=C(C5(C)C)OCC6=CC=C(C=C6)NC(=O)CC[C@@H](C(=O)OC)N)C#N)O)C)C)(C)C)C(=O)OC	IC50 > 200000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BPH2S4	2-(7-(5-(3-Cyano-5-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acid	Investigative	44138103	C23H15F3N4O4	468.4	C1CN2C3=C(C=C(C=C3)C4=NOC(=N4)C5=CC(=CC(=C5)C#N)OC(F)(F)F)C=C2C1CC(=O)O	IC50 > 400000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BQ53FV	Ecgonine methyl ester	Investigative	104904	C10H17NO3	199.25	CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)O)C(=O)OC	IC50 = 416869.38 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BR0DI5	(1r)-1-[(4-{[(6,7-Dihydro[1,4]dioxino[2,3-C]pyridazin-3-Yl)methyl]amino}piperidin-1-Yl)methyl]-9-Fluoro-1,2-Dihydro-4h-Pyrrolo[3,2,1-Ij]quinolin-4-One	Investigative	119057475	C24H26FN5O3	451.5	C1CN(CCC1NCC2=CC3=C(N=N2)OCCO3)C[C@@H]4CN5C(=O)C=CC6=C5C4=C(C=C6)F	IC50 = 238000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BS7A3X	2-[1-[2-Fluoro-4-[(5R)-2-oxo-5-(triazol-1-ylmethyl)-1,3-oxazolidin-3-yl]phenyl]piperidin-4-ylidene]propanenitrile	Investigative	71560403	C20H21FN6O2	396.4	CC(=C1CCN(CC1)C2=C(C=C(C=C2)N3C[C@@H](OC3=O)CN4C=CN=N4)F)C#N	IC50 = 213320 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BTKG52	8-[2-[4-(2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)piperidin-1-yl]ethyl]-2-methoxypyrido[2,3-d]pyrimidin-7-one	Investigative	56834577	C23H28N6O4	452.5	COC1=NC=C2C=CC(=O)N(C2=N1)CCN3CCC(CC3)NCC4=CC5=C(C=N4)OCCO5	IC50 = 206000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BU2J9X	Rhynchophylline	Investigative	5281408	C22H28N2O4	384.5	CC[C@H]1CN2CC[C@]3([C@@H]2C[C@@H]1/C(=C\\OC)/C(=O)OC)C4=CC=CC=C4NC3=O	IC50 = 773000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BV3GH5	2-[[2-[(3R)-3-Aminopiperidin-1-yl]-4-oxo-6-pyridin-3-yl-7H-pyrrolo[2,3-d]pyrimidin-3-yl]methyl]benzonitrile	Investigative	57385072	C24H23N7O	425.5	C1C[C@H](CN(C1)C2=NC3=C(C=C(N3)C4=CN=CC=C4)C(=O)N2CC5=CC=CC=C5C#N)N	IC50 > 300000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BVD35W	N-{4-[5-(4-Fluoro-phenyl)-3-methyl-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-acetamide	Investigative	11639342	C18H17FN4O2S	372.4	CC(=O)NC1=NC=CC(=C1)C2=C(N=C(N2C)S(=O)C)C3=CC=C(C=C3)F	IC50 = 213000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BVJH09	1-[(2S)-2-Amino-2-[(1r,4S)-4-[({3-oxo-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-6-yl}methyl)amino]cyclohexyl]ethyl]-7-methoxy-1,2-dihydro-1,5-naphthyridin-2-one	Investigative	46205341	C25H30N6O4	478.5	COC1=CC2=C(C=CC(=O)N2C[C@@H](C3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5)N)N=C1	IC50 > 333000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BVXU45	6-[[[4-[(1R)-1-Amino-2-(7-methoxy-2-oxoquinoxalin-1-yl)ethyl]cyclohexyl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one	Investigative	46205343	C25H30N6O4	478.5	COC1=CC2=C(C=C1)N=CC(=O)N2C[C@@H](C3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5)N	IC50 > 333000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BW7NM9	6-[[[1-[2-(2-Oxo-7-pyrimidin-5-yloxy-1,8-naphthyridin-1-yl)ethyl]piperidin-4-yl]amino]methyl]-4H-pyrido[3,2-b][1,4]oxazin-3-one	Investigative	122187097	C27H28N8O4	528.6	C1CN(CCC1NCC2=NC3=C(C=C2)OCC(=O)N3)CCN4C(=O)C=CC5=C4N=C(C=C5)OC6=CN=CN=C6	IC50 > 224000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BW8P3I	2-[[[4-[(1R)-1-Amino-2-(7-fluoro-4-methyl-2-oxoquinolin-1-yl)ethyl]cyclohexyl]amino]methyl]-8H-pyrimido[5,4-b][1,4]oxazin-7-one	Investigative	118720930	C25H29FN6O3	480.5	CC1=CC(=O)N(C2=C1C=CC(=C2)F)C[C@@H](C3CCC(CC3)NCC4=NC=C5C(=N4)NC(=O)CO5)N	IC50 > 333000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BX4F3B	(S)-4-((4-(((2,3-Dihydro-[1,4]dioxino[2,3-C]pyridin-7-Yl)methyl)amino)piperidin-1-Yl)methyl)-3-Fluoro-4-Hydroxy-4h-Pyrrolo[3,2,1-De][1,5]naphthyridin-7(5h)-One	Investigative	23633343	C24H26FN5O4	467.5	C1CN(CCC1NCC2=CC3=C(C=N2)OCCO3)C[C@@]4(CN5C(=O)C=CC6=NC=C(C4=C65)F)O	IC50 = 239000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	BYIR87	4-[[3-[4-(Pyrrolidin-1-ylmethyl)phenyl]cyclobutyl]methyl]morpholine	Investigative	11313056	C20H30N2O	314.5	C1CCN(C1)CC2=CC=C(C=C2)C3CC(C3)CN4CCOCC4	IC50 = 300000 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D02BPT	[3H]nicotine	Investigative	942	C10H14N2	162.23	CN1CCCC1C2=CN=CC=C2	IC50 = 245470.89 nM	Non binder
T20251	Voltage-gated potassium channel Kv11.1	D03WYU	CDDO-Me	Investigative	400769	C32H43NO4	505.7	C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)C(=O)OC	IC50 > 200000 nM	Non binder